Juno Therapeutics, Inc.
US ˙ NASDAQ
QUESTO SIMBOLO NON E' PIU' ATTIVO

SecurityJUNO / Juno Therapeutics, Inc.
InstitutionCommonwealth Equity Services, Inc
Latest Disclosed Ownership18,550 shares
Latest Disclosed Value $ 832,000
Commonwealth Equity Services, Inc reports 16.76% decrease in ownership of JUNO / Juno Therapeutics, Inc.

On February 16, 2018 - Commonwealth Equity Services, Inc filed a 13F-HR/A form disclosing ownership of 18,550 shares of Juno Therapeutics, Inc. (US:JUNO) valued at $832,000 USD as of September 30, 2017. The entity filed a previous 13F-HR/A on February 16, 2018 disclosing 22,285 shares of Juno Therapeutics, Inc.. This represents a change in shares of -16.76% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2018-02-16 2017-09-30 13F/A-1 JUNO THERAPEUTICS COM 48205A109 18,550 -3,735 -16.76 832 24.92 0.0050
2017-11-07 2017-09-30 13F JUNO THERAPEUTICS COM 48205A109 18,550 -3,735 832
2018-02-16 2017-06-30 13F/A-1 JUNO THERAPEUTICS COM 48205A109 22,285 225 1.02 666 35.92
2017-08-11 2017-06-30 13F JUNO THERAPEUTICS COM 48205A109 22,285 225 666
2018-02-16 2017-03-31 13F/A-1 JUNO THERAPEUTICS COM 48205A109 22,060 500 2.32 490 20.69
2017-05-15 2017-03-31 13F JUNO THERAPEUTICS COM 48205A109 22,060 500 490
2018-02-16 2016-12-31 13F/A-1 JUNO THERAPEUTICS COM 48205A109 21,560 -1,278 -5.60 406 -40.73
2017-02-01 2016-12-31 13F JUNO THERAPEUTICS COM 48205A109 21,560 -1,278 406
2016-10-25 2016-09-30 13F JUNO THERAPEUTICS COM 48205A109 22,838 -703 -2.99 685 -24.31
2016-08-04 2016-06-30 13F JUNO THERAPEUTICS COM 48205A109 23,541 2,031 9.44 905 10.50
2016-04-27 2016-03-31 13F JUNO THERAPEUTICS COM 48205A109 21,510 4,150 23.91 819 7.34
2016-01-19 2015-12-31 13F JUNO THERAPEUTICS COM 48205A109 17,360 1,700 10.86 763 19.78
2015-10-27 2015-09-30 13F JUNO THERAPEUTICS COM 48205A109 15,660 6,460 70.22 637 29.74
2015-07-28 2015-06-30 13F JUNO THERAPEUTICS COM 48205A109 9,200 3,150 52.07 491 33.79
2015-04-28 2015-03-31 13F JUNO THERAPEUTICS COM 48205A109 6,050 367
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.